Differential Function and Maturation of Human Stem Cell-Derived Islets After Transplantation

Area of Science:

• Regenerative Medicine
• Endocrinology
• Cell Therapy

Background:

• Stem cell-derived islets (SC-islets) offer a promising, abundant source for diabetes cell replacement therapy.
• SC-islets require in vivo maturation post-transplantation to achieve optimal function, unlike less mature in vitro differentiated cells.

Purpose of the Study:

• To investigate how cell dose, transplantation strategy, and host diabetic state impact SC-islet maturation and function.
• To establish optimal preclinical models for stem cell-based diabetes therapy.

Main Methods:

• Transplantation of varying SC-islet cell doses (0.75, 2, and 5 million) under the kidney capsule in diabetic mice.
• Comparison of subcutaneous (SQ) and intramuscular injections versus subcapsular transplantation.
• Assessment of diabetes reversal, SC-islet function, and expression of maturation markers (MAFA, FAM159B) in immunocompromised mice.

Main Results:

• Transplantation of 2 and 5 million SC-islet cells under the kidney capsule successfully reversed diabetes.
• Subcutaneous and intramuscular injections failed to reverse diabetes and showed no maturation marker expression.
• SC-islet function and maturation marker expression were consistent across diabetic and non-diabetic host states.

Conclusions:

• Transplantation parameters, specifically cell dose and delivery site, are critical for SC-islet efficacy in diabetes therapy.
• Subcapsular transplantation in mice provides a robust model for evaluating SC-islet function and maturation.
• Optimized transplantation strategies are essential for advancing stem cell-based diabetes treatments.